Original Study| Volume 15, ISSUE 6, e969-e975, December 2017

Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer

Published:April 25, 2017DOI:



      Radium-223 (223Ra) improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC). This retrospective analysis was performed to better understand its efficacy in routine clinical practice and identify factors associated with survival.

      Materials and Methods

      Sixty-four patients with mCRPC who received 223Ra between 2013 and 2015 were the basis of this retrospective study. Clinical outcomes and patient characteristics were obtained. Potential prognostic factors for survival were evaluated by univariate analysis using the log-rank test and multivariate analysis using the Cox proportional hazard method.


      The median survival was 12.9 months. Twenty-one patients (33%) developed a skeletal event, and the median time to the first skeletal event was 4.4 months. In univariate analysis, factors significantly associated with survival included: no prior chemotherapy, ≤ 5 bone metastases, baseline prostate-specific antigen (PSA) ≤ 36 ng/mL, baseline alkaline phosphatase (ALP) < 115 U/L, baseline hemoglobin > 12 g/dL, ALP response after 223Ra treatment, PSA decrease during 223Ra treatment, and absence of > 25% PSA increase during 223Ra treatment. In multivariate analysis, 4 factors remained significant: no prior chemotherapy, ≤ 5 bone metastases, baseline ALP < 115 U/L, and ALP response after 223Ra treatment.


      When 223Ra is administered in routine clinical practice, clinical outcomes can be more variable than those reported in the randomized study owing to patient heterogeneity. Four factors were identified to be significantly associated with survival after 223Ra treatment. These pretreatment factors may be used as stratification factors in future studies to investigate whether 223Ra would be more effective for patients with newly diagnosed metastatic disease that is sensitive to androgen deprivation therapy.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Petrylak D.P.
        • Tangen C.M.
        • Hussain M.H.
        • et al.
        Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
        N Engl J Med. 2004; 351: 1513-1520
        • Tannock I.F.
        • de Wit R.
        • Berry W.R.
        • et al.
        Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
        N Engl J Med. 2004; 351: 1502-1512
        • Parker C.
        • Nilsson S.
        • Heinrich D.
        • et al.
        Alpha emitter radium-223 and survival in metastatic prostate cancer.
        N Engl J Med. 2013; 369: 213-223
        • Nilsson S.
        • Cislo P.
        • Sartor O.
        • et al.
        Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.
        Ann Oncol. 2016; 27: 868-874
        • Etchebehere E.C.
        • Milton D.R.
        • Araujo J.C.
        • Swanston N.M.
        • Macapinlac H.A.
        • Rohren E.M.
        Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution.
        Eur J Nucl Med Mol Imaging. 2016; 43: 8-20
        • Etchebehere E.C.
        • Araujo J.C.
        • Fox P.S.
        • Swanston N.M.
        • Macapinlac H.A.
        • Rohren E.M.
        Prognostic factors in patients treated with 223Ra: the role of skeletal tumor burden on baseline 18F-fluoride PET/CT in predicting overall survival.
        J Nucl Med. 2015; 56: 1177-1184
        • Modi D.
        • Hwang C.
        • Mamdani H.
        • et al.
        Radium-223 in heavily pretreated metastatic castrate-resistant prostate cancer.
        Clin Genitourin Cancer. 2016; 14: 373-380e2
        • Hoskin P.
        • Sartor O.
        • O'Sullivan J.M.
        • et al.
        Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
        Lancet Oncol. 2014; 15: 1397-1406
        • Sweeney C.J.
        • Chen Y.H.
        • Carducci M.
        • et al.
        Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.
        N Engl J Med. 2015; 373: 737-746
        • James N.D.
        • Sydes M.R.
        • Clarke N.W.
        • et al.
        Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
        Lancet. 2016; 387: 1163-1177